Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.48 |
| ▸ | IL2 | P60568 | 1/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15274971 | 0.95 | TLR9 (0.47) | TLR9TLR8TLR7GPR119MAP3K11 | |
| SCHEMBL5538056 | 0.83 | DYRK1A (0.57) | TLR9TLR8TLR7METAP2 | |
| SCHEMBL15244897 | 0.81 | KCNH2 (0.56) | TLR9TLR8TLR7GPR119MAP3K11 | |
| SCHEMBL15244966 | 0.81 | KCNH2 (0.56) | TLR9TLR8TLR7GPR119MAP3K11 | |
| SCHEMBL19445556 | 0.78 | TLR9 (0.39) | TLR9TLR8TLR7GPR119MAP3K11 | |
| SCHEMBL10198628 | 0.78 | PIM1 (0.50) | — | |
| SCHEMBL3442195 | 0.76 | GPR119 (0.59) | GPR119KCNH2CACNA1CASIC3NTRK1 | |
| SCHEMBL23601164 | 0.75 | KCNH2 (0.57) | TLR9TLR8TLR7GPR119IL2 | |
| SCHEMBL12911533 | 0.75 | GPR119 (0.58) | GPR119KCNH2CACNA1CASIC3CNR2 | |
| SCHEMBL12911528 | 0.75 | GPR119 (0.58) | TLR9TLR8TLR7GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2012006315-A2 | METHODS OF IMMUNE MODULATION | POLYMEDIX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| WO-2010014573-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | TLR9 12/4885TLR8 19/4885TLR7 27/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | TLR9 12/4885TLR8 19/4885TLR7 27/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | TLR9 12/4885TLR8 19/4885TLR7 27/4885 |
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | TLR9 11/4885TLR8 39/4885TLR7 48/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | TLR9 11/4885TLR8 39/4885TLR7 48/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | TLR9 27/4885TLR8 32/4885TLR7 92/4885 |
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | TLR9 2121/4885TLR8 802/4885TLR7 1438/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | TLR9 12/4885TLR8 19/4885TLR7 27/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | TLR9 27/4885TLR8 32/4885TLR7 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.